Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

183
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
183
Psychosurgery01:30

Psychosurgery

41
Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
41
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

117
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
117
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

271
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
271
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

285
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
285

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program.

The international journal of neuropsychopharmacology·2026
Same author

Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine.

International journal of psychiatry in clinical practice·2026
Same author

The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus.

The British journal of psychiatry : the journal of mental science·2026
Same author

Expert consensus on the use of trazodone in patients with major depressive disorder: results from a European Delphi panel.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Neurotransmitter alterations in seasonal affective disorder.

Scientific reports·2026
Same journal

Retraction Statement: Psychometric properties of the Female Sexual Distress Scale-Revised among a sample of non-clinical Iranian women.

International journal of psychiatry in clinical practice·2026
Same journal

Biological and social rhythm differences, daily melatonin secretion and psychiatric symptoms in healthy adults.

International journal of psychiatry in clinical practice·2026
Same journal

Diagnostic utility of pan-immune inflammation value in drug-naïve first-episode psychosis.

International journal of psychiatry in clinical practice·2026
Same journal

Examining neuroretinal alterations in autism spectrum disorder: a systematic review of OCT and OCT-A studies.

International journal of psychiatry in clinical practice·2026
Same journal

Depressive symptoms in patients with schizophrenia spectrum disorders and the impact on treatment motivation and satisfaction.

International journal of psychiatry in clinical practice·2026
Same journal

Predictors of premature treatment termination in an inpatient programme for women with PTSD and/or eating disorders.

International journal of psychiatry in clinical practice·2026
See all related articles

Related Experiment Video

Updated: May 28, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.2K

KET or ECT for treatment-resistant depression?

M Spies1,2, S Kasper3, R Frey1,2

  • 1Department of Psychiatry and Psychotherapy, Clinical Division of General Psychiatry, Medical University of Vienna, Austria.

International Journal of Psychiatry in Clinical Practice
|February 10, 2025
PubMed
Summary
This summary is machine-generated.

Electroconvulsive therapy (ECT) and ketamine are effective for treatment-resistant depression (TRD). Comparative studies have limitations, suggesting personalized treatment decisions based on clinical markers and patient preference are crucial for TRD.

Keywords:
Electroconvulsive therapyinferiorityketamineresponsetreatment-resistant depression

More Related Videos

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.0K
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

22.2K

Related Experiment Videos

Last Updated: May 28, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.2K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.0K
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

22.2K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Clinical Medicine

Background:

  • Modern electroconvulsive therapy (ECT) and ketamine are leading treatments for treatment-resistant depression (TRD).
  • Recent head-to-head studies comparing ECT and ketamine for TRD have produced conflicting results.
  • Methodological differences in patient characteristics and treatment protocols limit the interpretation of comparative studies.

Purpose of the Study:

  • To address the limitations in comparative studies of ECT and ketamine for TRD.
  • To propose a framework for treatment decisions in TRD.
  • To highlight the need for further research on ECT efficacy in ketamine non-responders.

Main Methods:

  • Commentary on a recent randomized clinical trial comparing ketamine and ECT for TRD.
  • Analysis of methodological differences in existing comparative studies.
  • Literature review on treatment options for TRD.

Main Results:

  • Both ECT and ketamine are highly effective for TRD.
  • Incongruent findings in head-to-head comparisons are attributed to patient heterogeneity and procedural variations.
  • Predictive clinical response markers and patient preferences should guide treatment selection.

Conclusions:

  • Treatment decisions for TRD should integrate clinical predictors and patient preferences, considering the distinct side effect profiles of ECT and ketamine.
  • Further research is needed to evaluate the efficacy of ECT in patients who do not respond to ketamine.
  • Personalized medicine approaches are essential for optimizing TRD treatment outcomes.